Last reviewed · How we verify
discontinuation of aspirin therapy
discontinuation of aspirin therapy is a Small molecule drug developed by Hadassah Medical Organization. It is currently FDA-approved.
The discontinuation of aspirin therapy, marketed by Hadassah Medical Organization, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. A key strength is the established market presence, leveraging the well-known efficacy and safety profile of aspirin. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | discontinuation of aspirin therapy |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study (PHASE4)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
- OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- discontinuation of aspirin therapy CI brief — competitive landscape report
- discontinuation of aspirin therapy updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI